NeoRX Corporation

NeoRx Corporation develops innovative therapeutic biopharmaceuticals primarily for the treatment of cancer, cardiovascular, and inflammatory diseases. As part of its cancer treatment program, NeoRx is currently conducting a Phase I trial of its Skeletal Targeted Radiation ("STR") product combined with chemotherapy in patients with multiple myeloma. NeoRx is also developing a proprietary PRETARGET-REGISTERED TRADEMARK- platform for the delivery of therapeutic products directly to tumor sites.

Contact Details: 410 West Harrison Street Seattle Washington 98119-4007 United States of America Tel: 206 281 7001 Fax: 206 284 7112 Email: WWW: www.neorx.com/

Loading...

Recent Publications by NeoRX Corporation:
166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy. 166Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonate...	28th April, 2006	NeoRx Corp., Seattle,	J Nucl Med. 2006 Mar;47(3):534-42.
Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator. OBJECTIVE: Pretargeting is the concept that combines optimal delivery of...	11th March, 2006	NeoRx Corp., Seattle, WA 98119, USA.	Nucl Med Biol. 2005 Oct;32(7):741-7. DOI Direct Link
Clinical aspects of radiation nephropathy. Small radiolabeled molecules are finding increasing clinical use for...	12th January, 2005	NeoRx Corporation, 300 Elliott Avenue W, #500 Seattle, WA 98119, USA.	Cancer Biother Radiopharm. 2004 Jun;19(3):359-62. DOI Direct Link
Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Pretarget radioimmunotherapy (RIT) is a multistep strategy for cancer...	29th May, 2004	NeoRx Corporation, Seattle, Washington 98119-4114, USA.	Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3712-21.
Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP. A study was undertaken to determine the maximum tolerated dose of...	13th January, 2004	NeoRx Corporation,	Cancer Biother Radiopharm. 2003 Apr;18(2):225-30. DOI Direct Link
→View more NeoRX Corporation research publications.

BioNews Results for NeoRX Corporation:
Poniard rebounds on picoplatin colon cancer data	Seattle Times:  Nov 17 2009 7:48PM Matching: neorx

NeoRX Corporation Patents:
US Patent No.	Title
5955605	Biotinidase resistant biotin-DOTA conjugates
6171609	Therapeutic inhibitor of vascular smooth muscle cells
6172045	Cluster clearing agents
6177551	Bridged aromatic substituted amine ligands with donor atoms
6187910	Bridged aromatic substituted amine ligands with donor atoms
→View more NeoRX Corporation patents.

NeoRX Corporation (NERX) Financial information Links from Barchart
NERX Quote from from Barchart.com
NERX Chart from from Barchart.com
NERX Profile from from Barchart.com
NERX Opinion from from Barchart.com
→View more NeoRX Corporation finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 11 individuals from NeoRX Corporation using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 488 times since April 2007, the link to the organisation's website has been followed 124 times

Recent Search Terms used to find this page: neorx corp | NEO RX CORP | neorx corporation | neorx corporation | Neorx Corp | NeoRx Corp DoTA-biotin | 410 west harrison building seattle | dota biotin NeoRx | neo rx seattle | neo rx seattle | .

Search for more companies in Seattle

Search for more companies in Washington

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for NeoRX Corporation